Ligand Pharmaceuticals Incorporated
LGND
$104.97
$0.350.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -17.37% | 24.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.37% | 24.76% | |||
| Cost of Revenue | -10.61% | -1.65% | |||
| Gross Profit | -18.63% | 31.31% | |||
| SG&A Expenses | 4.62% | 38.88% | |||
| Depreciation & Amortization | 0.00% | 0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.66% | 19.67% | |||
| Operating Income | -84.60% | 48.22% | |||
| Income Before Tax | -518.39% | 90.31% | |||
| Income Tax Expenses | -1,073.83% | 106.18% | |||
| Earnings from Continuing Operations | -333.46% | 86.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -333.46% | 86.18% | |||
| EBIT | -84.60% | 48.22% | |||
| EBITDA | -48.30% | 22.81% | |||
| EPS Basic | -320.78% | 86.48% | |||
| Normalized Basic EPS | 261.83% | 65.26% | |||
| EPS Diluted | -320.85% | 86.46% | |||
| Normalized Diluted EPS | 261.83% | 65.26% | |||
| Average Basic Shares Outstanding | 3.01% | 2.17% | |||
| Average Diluted Shares Outstanding | 3.01% | 2.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||